tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2024-011tumors-1411Research ArticleОБЗОРЫ И АНАЛИТИКАREVIEWS AND ANALYSISБиопсия сторожевых лимфоузлов при раке эндометрия: современное состояние вопроса (обзор литературы)Sentinel lymph node biopsy in endometrial cancer: current status (literature review)https://orcid.org/0000-0002-4118-9642СорокинП. И.SorokinP. I.

Сорокин Павел Игоревич

143515 Московская область, п. Истра, 27

Sorokin Pavel Igorevich

22 Istra, Moscow Region 143515

sor-pavel@ya.ruhttps://orcid.org/0009-0008-2374-9133НовожиловМ. В.NovozhilovM. V.

Новожилов Михаил Васильевич

143515 Московская область, п. Истра, 27

Novozhilov Mikhail Vasilevich

22 Istra, Moscow Region 143515

https://orcid.org/0000-0002-6620-2073УткинД. О.UtkinD. O.

Уткин Дмитрий Олегович

143515 Московская область, п. Истра, 27

Utkin Dmitrii Olegovich

22 Istra, Moscow Region 143515

https://orcid.org/0009-0005-0424-8753АбдурагимоваЗ. Т.AbduragimovaZ. T.

Абдурагимова Зарема Тагировна

143515 Московская область, п. Истра, 27

Abduragimova Zarema Tagirovna

22 Istra, Moscow Region 143515

https://orcid.org/0009-0006-5317-5682ТищенкоМ. А.TishenkoM. A.

Тищенко Марина Александровна

143515 Московская область, п. Истра, 27

Tishchenko Marina Aleksandrovna

22 Istra, Moscow Region 143515

https://orcid.org/0000-0001-8591-3797ЖароваА. С.ZharovaA. S.

Жарова Алена Сергеевна

143515 Московская область, п. Истра, 27

Zharova Alena Sergeevna

22 Istra, Moscow Region 143515

https://orcid.org/0000-0001-8399-5231КуликоваС. Е.KulikovaS. E.

Куликова Светлана Евгеньевна

143515 Московская область, п. Истра, 27

Kulikova Svetlana Evgenevna

22 Istra, Moscow Region 143515

ГБУЗ г. Москвы «Московская городская онкологическая больница No 62 Департамента здравоохранения г. Москвы»РоссияMoscow City Oncology Hospital No. 62 Moscow Healthcare DepartmentRussian Federation2024181220241435664Copyright © Сорокин П.И., Новожилов М.В., Уткин Д.О., Абдурагимова З.Т., Тищенко М.А., Жарова А.С., Куликова С.Е., 20242024Сорокин П.И., Новожилов М.В., Уткин Д.О., Абдурагимова З.Т., Тищенко М.А., Жарова А.С., Куликова С.Е.Sorokin P.I., Novozhilov M.V., Utkin D.O., Abduragimova Z.T., Tishenko M.A., Zharova A.S., Kulikova S.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/1411

Рак эндометрия — это самая частая опухоль женской репродуктивной системы в России и в мире. Определение статуса лимфоузлов является важным этапом хирургического стадирования, от которого зависит прогноз и тактика адъювантной терапии. Системная тазовая и забрюшинная лимфаденэктомия является золотым стандартом стадирования рака эндометрия. Высокая травматичность и долгосрочное влияние на качество жизни сдерживают использование этой методики у всех пациенток. Концепция биопсии сторожевых лимфоузлов является альтернативой системной лимфаденэктомии. Мы провели обзор литературы, чтобы определить современное состояние вопроса, диагностическую роль и безопасность этой процедуры для раннего рака эндометрия.

Endometrial cancer is the most common gynaecological malignancy in Russia and in the world. Pathological evaluation of lymph nodes is important for staging and adjuvant therapy management. Until recently, systematic lymphadenectomy was the gold standard for staging of endometrial cancer. However, this procedure has been associated with high morbidity and life-long consequences. Sentinel lymph node biopsy is an alternative procedure for staging. We conducted a literature review to evaluate the diagnostic precision, safety and methodology of sentinel lymph node mapping in endometrial cancer.

рак эндометриястадированиесторожевые лимфатические узлыбиопсия сторожевых лимфоузловиндоцианин зеленыйendometrial cancerstagingsentinel lymph nodessentinel lymph node biopsyindocyanine greenСтатья подготовлена без спонсорской поддержкиThe article was prepared without sponsorshipReferencesСабанцев М.А., Шрамко С.В., Жилина Н.М. и соавт.. Рак эндометрия: динамика заболеваемости и распространенности за период 2004-2021 гг. в России и Новокузнецке. Бюллетенв медицинской науки 2023;1(29):16-23. https://doi.org/10.31684/25418475-2023-l-16.Sabantsev М.А., Shramko S.V., Zhilina N.M., et al. Trends in incidence and prevalence of endometrial cancer in Russia and Novokuznetsk: a 2004-2021 study. Bulletin of Medical Science. 2023;l(29):16—23. (In Russ.). https://doi.org/10.31684/25418475-2023-1-16Kitchener H., Swart A.M.C., Qian Q., et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MR.C ASTEC trial): arandomised study. Lancet 2009;373(9658)125-136.https://doi.org/10.1016/S0140-6736(08)61766-3Kitchener H., Swart A.M.C., Qian Q., et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MR.C ASTEC trial): arandomised study. Lancet 2009;373(9658)125-136.https://doi.org/10.1016/S0140-6736(08)61766-3Panici P.B., Basile S., Maneschi F., et al. Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008;100(23):1707-1716.https://doi.org/10.1093/jnci/djn397Panici P.B., Basile S., Maneschi F., et al. Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008;100(23):1707-1716.https://doi.org/10.1093/jnci/djn397Князев Р.И., Жорданиа К.И., Шевчук A.C. Хирургические факторы риска развития лимфатических кист после тазовой лимфаденэктомии у болвных раком тела матки. Онкогинекология 2021;1(37):57-64.KnyazevR.I., Zhordania K.I., Shevchyuk A.S. Surgery-related risk factors for lymphocyst formation after pelvic lymphadenectomy in patients with endometrial cancer. Onkoginekologiya2021;l(37):57-64. (In Russ.)Burke T.W., Levenback C., Tornos C., et al. Intraabdominal lymphatic mapping to direct selective pelvic and paraaortic lymphadenectomy in women with high-risk endometrial cancer: results of a pilot study. Gynecol Oncol 1996;62(2):169-173. https://doi.org/10.1006/gyno.1996.0211Burke T.W., Levenback C., Tornos C., et al. Intraabdominal lymphatic mapping to direct selective pelvic and paraaortic lymphadenectomy in women with high-risk endometrial cancer: results of a pilot study. Gynecol Oncol 1996;62(2):169-173. https://doi.org/10.1006/gyno.1996.0211Halsted W.S.I. The results of radical operations for the cure of carcinoma of the breast. Ann Surg 1907;46(l):l—19. https://doi.org/10.1097/00000658-190707000-00001Halsted W.S.I. The results of radical operations for the cure of carcinoma of the breast. Ann Surg 1907;46(l):l—19. https://doi.org/10.1097/00000658-190707000-00001Cady B. Basic principles in surgical oncology. Arch Surg 1997;132(4):338-346.https://doi.org/10.1001/archsurg.1997.01430280012001Cady B. Basic principles in surgical oncology. Arch Surg 1997;132(4):338-346.https://doi.org/10.1001/archsurg.1997.01430280012001Odicino F., Pecorelli S., Zigliani L., Creasmanet W.T. History of the FIGO cancer staging system. Int J Gynecol Obstet 2008;101(2):205-210.https://doi.org/10.1016/j.ijgo.2007.11.004Odicino F., Pecorelli S., Zigliani L., Creasmanet W.T. History of the FIGO cancer staging system. Int J Gynecol Obstet 2008;101(2):205-210.https://doi.org/10.1016/j.ijgo.2007.11.004Нечушкина B.M., Коломиец Л.А., Кравец O.A. и соавт. Практические рекомендации по лекарственному лечению рака тела матки и сарком матки. Злокачественные опухоли 2023;13(3s2):263—279. https://doi.org/10.18027/2224-5057-2023-13-3s2-l-263-279Nechushkina V.M., Kolomiets L.A., Kravets O.A., et al. Practical recommendations for drug treatment of uterine cancer and uterine sarcomas. Zlokachestvennie opuholi = Malignant Tumors 2023;13(3s2):263-279. (In Russ.). https://doi.org/10.18027/2224-5057-2023-13-3s2-l-263-279Bokhman J.V. Two pathogenetic types of endometrial carcinoma. GynecolOncol 1983;15(l):10-17.https://doi.org/10.1016/0090-8258(83)90111-7Bokhman J.V. Two pathogenetic types of endometrial carcinoma. GynecolOncol 1983;15(l):10-17.https://doi.org/10.1016/0090-8258(83)90111-7Kandoth C., Schultz N., Cherniack A.D., et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497(7447):67-73.https://doi.org/10.1038/naturel2113Kandoth C., Schultz N., Cherniack A.D., et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497(7447):67-73.https://doi.org/10.1038/naturel2113Berek J.S., Matias-Guiu X., Creutzberg C., et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 2023;162(2):383-394. https://doi.org/10.1002/ijgo.14923Berek J.S., Matias-Guiu X., Creutzberg C., et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 2023;162(2):383-394. https://doi.org/10.1002/ijgo.14923Kim C.H., Soslow R.A., Parket K.J., et al. Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging. Int J Gynecol Cancer 2013;23(5):964-970. https://doi.org/10.1097/IGC.0b013e3182954da8Kim C.H., Soslow R.A., Parket K.J., et al. Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging. Int J Gynecol Cancer 2013;23(5):964-970. https://doi.org/10.1097/IGC.0b013e3182954da8Papadia A., Zapardiel I., Bussi B., et al. Sentinel lymph node mapping in patients with stage I endometrial carcinoma: a focus on bilateral mapping identification by comparing radiotracer Tc99 m with blue dye versus indocyanine green fluorescent dye //Journal of cancer research and clinical oncology. J Cancer Res Clin Oncol 2017;143(3):475-480. https://doi.org/10.1007/s00432-016-2297-yPapadia A., Zapardiel I., Bussi B., et al. Sentinel lymph node mapping in patients with stage I endometrial carcinoma: a focus on bilateral mapping identification by comparing radiotracer Tc99 m with blue dye versus indocyanine green fluorescent dye //Journal of cancer research and clinical oncology. J Cancer Res Clin Oncol 2017;143(3):475-480. https://doi.org/10.1007/s00432-016-2297-yHolloway R.W., Abu-Rustum N.R., Backes F.J., et al. Sentinel lymph node mapping and staging in endometrial cancer: a Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol Oncol 2017;146(2):405— 415.https://doi.org/10.1016/j.ygyno.2017.05.027Holloway R.W., Abu-Rustum N.R., Backes F.J., et al. Sentinel lymph node mapping and staging in endometrial cancer: a Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol Oncol 2017;146(2):405— 415.https://doi.org/10.1016/j.ygyno.2017.05.027Eriksson A.G.Z., Beavis A., Soslow R.A., et al. A comparison of the detection of sentinel lymph nodes using indocyanine green and near-infrared fluorescence imaging versus blue dye during robotic surgery in uterine cancer. Int J Gynecol Cancer 2017;27(4):743-747.https://doi.org/10.1097/IGC.0000000000000959Eriksson A.G.Z., Beavis A., Soslow R.A., et al. A comparison of the detection of sentinel lymph nodes using indocyanine green and near-infrared fluorescence imaging versus blue dye during robotic surgery in uterine cancer. Int J Gynecol Cancer 2017;27(4):743-747.https://doi.org/10.1097/IGC.0000000000000959Ditto A., Casarin I., Pinelli C., et al. Hysteroscopic versus cervical injection for sentinel node detection in endometrial cancer: A multicenter prospective randomised controlled trial from the Multicenter Italian Trials in Ovarian cancer (MITO) studygroup. EurJ Cancer2020;140:l-10.https://doi.org/10.1016/j.ejca.2020.08.030Ditto A., Casarin I., Pinelli C., et al. Hysteroscopic versus cervical injection for sentinel node detection in endometrial cancer: A multicenter prospective randomised controlled trial from the Multicenter Italian Trials in Ovarian cancer (MITO) studygroup. EurJ Cancer2020;140:l-10.https://doi.org/10.1016/j.ejca.2020.08.030Cormier B., Rozenholc A.T., Gotlieb W., et al. Sentinel lymph node procedure in endometrial cancer: a systematic review and proposal for standardization of future research. Gynecol Oncol 2015;138(2):478-485.https://doi.org/10.1016/j.ygyno.2015.05.039Cormier B., Rozenholc A.T., Gotlieb W., et al. Sentinel lymph node procedure in endometrial cancer: a systematic review and proposal for standardization of future research. Gynecol Oncol 2015;138(2):478-485.https://doi.org/10.1016/j.ygyno.2015.05.039Creasman W.T., Morrow C.P., Bundy B.N., et al. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study. Cancer 1987;60(8S):2035-2041.https://doi.org/10.1002/1097-0142(19901015)60:8+<2035::aid-cncr2820601515>3.0.co;2-8Creasman W.T., Morrow C.P., Bundy B.N., et al. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study. Cancer 1987;60(8S):2035-2041.https://doi.org/10.1002/1097-0142(19901015)60:8+<2035::aid-cncr2820601515>3.0.co;2-8Abu-Rustum N.R., Gomez J.D., Alektiar K.M., et al. The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes. Gynecol Oncol 2009;115(2):236-238.https://doi.org/10.1016/j.ygyno.2009.07.016Abu-Rustum N.R., Gomez J.D., Alektiar K.M., et al. The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes. Gynecol Oncol 2009;115(2):236-238.https://doi.org/10.1016/j.ygyno.2009.07.016Rossi E.C., Kowalski L.D., Scalici J., et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol 2017;18(3):384-392.https://doi.org/10.1016/S1470-2045(17)30068-2Rossi E.C., Kowalski L.D., Scalici J., et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol 2017;18(3):384-392.https://doi.org/10.1016/S1470-2045(17)30068-2Persson J., Salehi S., Bollino M., et al. Pelvic Sentinel lymph node detection in High-Risk Endometrial Cancer (SHRECtrial)-the final step towards a paradigm shift in surgical staging. Eur J Cancer 2019;116:77-85.https://doi.org/10.1016/j.ejca.2019.04.025Persson J., Salehi S., Bollino M., et al. Pelvic Sentinel lymph node detection in High-Risk Endometrial Cancer (SHRECtrial)-the final step towards a paradigm shift in surgical staging. Eur J Cancer 2019;116:77-85.https://doi.org/10.1016/j.ejca.2019.04.025Chan J.K., Cheung M.K., Huh W.K., et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer 2006;107(8):1823-1830. https://doi.org/10.1002/cncr.22185Chan J.K., Cheung M.K., Huh W.K., et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer 2006;107(8):1823-1830. https://doi.org/10.1002/cncr.22185Todo Y., Kato H., Kaneuchi M., et al. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 2010;375(9721):1165-1172. https://doi.org/10.1016/S0140-6736(09)62002-XTodo Y., Kato H., Kaneuchi M., et al. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 2010;375(9721):1165-1172. https://doi.org/10.1016/S0140-6736(09)62002-XSormani M.P. The Will Rogers phenomenon: the effect of different diagnostic criteria. J Neurol Sci 2009;287:S46-S49. https://doi.org/10.1016/S0022-510X(09)71300-0Sormani M.P. The Will Rogers phenomenon: the effect of different diagnostic criteria. J Neurol Sci 2009;287:S46-S49. https://doi.org/10.1016/S0022-510X(09)71300-0Emons G., Kim J.-W., Weide K., et al. Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence; AGO'OP. 6). Int J Gynecol Cancer2021;31(7):1075-1079.https://doi.org/10.1136/ijgc-2021-002703Emons G., Kim J.-W., Weide K., et al. Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence; AGO'OP. 6). Int J Gynecol Cancer2021;31(7):1075-1079.https://doi.org/10.1136/ijgc-2021-002703Park J.Y., Kim J.H., Baek M.H., et al. Randomized comparison between sentinel lymph node mapping using indocyanine green plus a fluorescent camera versus lymph node dissection in clinical stage I'll endometrial cancer: a Korean Gynecologic Oncology Group trial (KGOG2029/SELYE). J Gynecol Oncol 2022;33(6):e73. https://doi.org/10.3802/jgo.2022.33.e73Park J.Y., Kim J.H., Baek M.H., et al. Randomized comparison between sentinel lymph node mapping using indocyanine green plus a fluorescent camera versus lymph node dissection in clinical stage I'll endometrial cancer: a Korean Gynecologic Oncology Group trial (KGOG2029/SELYE). J Gynecol Oncol 2022;33(6):e73. https://doi.org/10.3802/jgo.2022.33.e73Guo Y., Sun L., Chen X., et al. A multicenter noninferior randomized controlled study of sentinel lymph node biopsy alone versus sentinel lymph node biopsy plus lymphadenectomy for patients with stage I endometrial cancer, INSEC trial concept. BMC cancer 2023;23(l):1184. https://doi.org/10.1186/sl2885-023-11226-lGuo Y., Sun L., Chen X., et al. A multicenter noninferior randomized controlled study of sentinel lymph node biopsy alone versus sentinel lymph node biopsy plus lymphadenectomy for patients with stage I endometrial cancer, INSEC trial concept. BMC cancer 2023;23(l):1184. https://doi.org/10.1186/sl2885-023-11226-lObermair A., Nicklin J., Gebskiet V., et al. A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer-ENDO-3: ANZGOG trial 1911/2020. IntJ Gynecol Cancer 2021;31(12):1595—1601. https://doi.org/10.1136/ijgc-2021-003029Obermair A., Nicklin J., Gebskiet V., et al. A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer-ENDO-3: ANZGOG trial 1911/2020. IntJ Gynecol Cancer 2021;31(12):1595—1601. https://doi.org/10.1136/ijgc-2021-003029Eriksson A.G.Z., Ducie J., Ali N., et al. Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion. Gynecol Oncol 2016;140(3):394-399.https://doi.org/10.1016/j.ygyno.2015.12.028Eriksson A.G.Z., Ducie J., Ali N., et al. Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion. Gynecol Oncol 2016;140(3):394-399.https://doi.org/10.1016/j.ygyno.2015.12.028Jaafar E., Gaultier V., Wohrer H., et al. Impact of sentinel lymph node mapping on survival in patients with high-risk endometrial cancer in the early stage: A matched cohort study. IntJ GynaecolObstet 2024;165(2):677-684. https://doi.org/10.1002/ijgo.l5315Jaafar E., Gaultier V., Wohrer H., et al. Impact of sentinel lymph node mapping on survival in patients with high-risk endometrial cancer in the early stage: A matched cohort study. IntJ GynaecolObstet 2024;165(2):677-684. https://doi.org/10.1002/ijgo.l5315Capozzi V.A., Rosati A., Maglietta G., et al. Long-term survival outcomes in high-risk endometrial cancer patients undergoing sentinel lymph node biopsy alone versus lymphadenectomy. Int J Gynecol Cancer 2023;33(7):1013-1020. https://doi.org/10.1136/ijgc-2023-004314Capozzi V.A., Rosati A., Maglietta G., et al. Long-term survival outcomes in high-risk endometrial cancer patients undergoing sentinel lymph node biopsy alone versus lymphadenectomy. Int J Gynecol Cancer 2023;33(7):1013-1020. https://doi.org/10.1136/ijgc-2023-004314Nasioudis D., Byrne M., Ko E. M, et al. The impact of sentinel lymph node sampling versus traditional lymphadenectomy on the survival of patients with stage IIIC endometrial cancer. IntJ Gynecol Cancer 2021;31(6):840-845.https://doi.org/10.1136/ijgc-2021-002450Nasioudis D., Byrne M., Ko E. M, et al. The impact of sentinel lymph node sampling versus traditional lymphadenectomy on the survival of patients with stage IIIC endometrial cancer. IntJ Gynecol Cancer 2021;31(6):840-845.https://doi.org/10.1136/ijgc-2021-002450Ignatov A., Papathemelis T., Ivros S., et al. Comparison of survival of patients with endometrial cancer undergoing sentinel node biopsy alone or systematic lymphadenectomy. Arch Gynecol Obstet 2020;302(4):995-1000. https://doi.org/10.1007/s00404-020-05698-wIgnatov A., Papathemelis T., Ivros S., et al. Comparison of survival of patients with endometrial cancer undergoing sentinel node biopsy alone or systematic lymphadenectomy. Arch Gynecol Obstet 2020;302(4):995-1000. https://doi.org/10.1007/s00404-020-05698-wMatsuo K., Klar M., Khetan V.U., et al. Sentinel lymph node biopsy for stage II endometrial cancer: recent utilization and outcome in the United States. Gynecol Oncol 2022;164(l):46-52.https://doi.org/10.1016/j.ygyno.2021.10.085Matsuo K., Klar M., Khetan V.U., et al. Sentinel lymph node biopsy for stage II endometrial cancer: recent utilization and outcome in the United States. Gynecol Oncol 2022;164(l):46-52.https://doi.org/10.1016/j.ygyno.2021.10.085Abu-Rustum N., Yashar C., Arend R., et al. Uterine Neoplasms, Version 1.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Cane Netw 2023;21(2):181-209. https://doi.org/10.6004/jnccn.2023.0006Abu-Rustum N., Yashar C., Arend R., et al. Uterine Neoplasms, Version 1.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Cane Netw 2023;21(2):181-209. https://doi.org/10.6004/jnccn.2023.0006Concin N., Matias-Guiu X., Creutzberg C.L., et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. IntJ Gynecol Cancer 2021;31(l):12—39. https://doi.org/10.1136/ijgc-2020-002230Concin N., Matias-Guiu X., Creutzberg C.L., et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. IntJ Gynecol Cancer 2021;31(l):12—39. https://doi.org/10.1136/ijgc-2020-002230Fotopoulou C., Ind T., Baldwin P., et al. Sentinel lymph node consensus document of the British Gynaecological Cancer Society for endometrial, vulvar, and cervical cancers. IntJ Gynecol Cancer 2019;29(9):1348-1350.https://doi.org/10.1136/ijgc-2019-000798Fotopoulou C., Ind T., Baldwin P., et al. Sentinel lymph node consensus document of the British Gynaecological Cancer Society for endometrial, vulvar, and cervical cancers. IntJ Gynecol Cancer 2019;29(9):1348-1350.https://doi.org/10.1136/ijgc-2019-000798Рак тела матки и саркомы матки. Клинические рекомендации2020 г. Доступно по: https://old.oncology-association.ru/files/clinical-guidelines-2020/rak_tela_matki_i_sarkomy_matki.pdf.Cancer of the body of the uterus and sarcoma of the uterus. Clinical guidelines of 2020. Available at: https://old.oncology-association.ru/files/clinical-guidelines-2020/rak_tela_matki_i_sarkomy_matki.pdf.(ln Russ.)Accorsi G.S., Paiva L.L., Schmidt R., et al. Sentinel lymph node mapping vs systematic lymphadenectomy for endometrial cancer: surgical morbidity and lymphatic complications. J Minim Invasive Gynecol 2020;27(4):938-945.e2.https://doi.org/10.1016/j.jmig.2019.07.030Accorsi G.S., Paiva L.L., Schmidt R., et al. Sentinel lymph node mapping vs systematic lymphadenectomy for endometrial cancer: surgical morbidity and lymphatic complications. J Minim Invasive Gynecol 2020;27(4):938-945.e2.https://doi.org/10.1016/j.jmig.2019.07.030Geppert B., Lonnerfors C., Bollino M., Persson J. Sentinel lymph node biopsy in endometrial cancer—feasibility, safety andlymphatic complications. Gynecol Oncol 2018;148(3):491-498. https://doi.Org/10.1016/j.ygyno.2017.12.017Geppert B., Lonnerfors C., Bollino M., Persson J. Sentinel lymph node biopsy in endometrial cancer—feasibility, safety andlymphatic complications. Gynecol Oncol 2018;148(3):491-498. https://doi.Org/10.1016/j.ygyno.2017.12.017Diniz T.P., Drizlionoks E., Faloppaet C.C., et al. Impact of sentinel node mapping in decreasing the risk of lymphocele in endometrial cancer. Ann Surg Oncol 2021;28(6):3293-3299. https://doi.org/10.1245/sl0434-020-09282-zDiniz T.P., Drizlionoks E., Faloppaet C.C., et al. Impact of sentinel node mapping in decreasing the risk of lymphocele in endometrial cancer. Ann Surg Oncol 2021;28(6):3293-3299. https://doi.org/10.1245/sl0434-020-09282-zBaiocchi G., Andrade C.E.M.C., Ribeiro R., et al. Sentinel lymph node mapping versus sentinel lymph node mapping with systematic lymphadenectomy in endometrial cancer: an open-label, non-inferiority, randomized trial (ALICE trial). IntJ Gynecol Cancer 2022;32(5):676-679.https://doi.org/10.1136/ijgc-2022-003378Baiocchi G., Andrade C.E.M.C., Ribeiro R., et al. Sentinel lymph node mapping versus sentinel lymph node mapping with systematic lymphadenectomy in endometrial cancer: an open-label, non-inferiority, randomized trial (ALICE trial). IntJ Gynecol Cancer 2022;32(5):676-679.https://doi.org/10.1136/ijgc-2022-003378Capasso I., GarzonS., Kumar S., et al. Prognostic factors in patients with endometrial cancer with isolated lymphatic recurrence. IntJ Gynecol Cancer 2023;33(8):1169-1178.https://doi.org/10.1136/ijgc-2023-004435Capasso I., GarzonS., Kumar S., et al. Prognostic factors in patients with endometrial cancer with isolated lymphatic recurrence. IntJ Gynecol Cancer 2023;33(8):1169-1178.https://doi.org/10.1136/ijgc-2023-004435Plante M., Stanleigh J., Renaud М.-C., et al. Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: does adjuvant treatment matter? Gynecol Oncol 2017;146(2):240-246.https://doi.org/10.1016/j.ygyno.2017.05.024Plante M., Stanleigh J., Renaud М.-C., et al. Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: does adjuvant treatment matter? Gynecol Oncol 2017;146(2):240-246.https://doi.org/10.1016/j.ygyno.2017.05.024St. Clair C.M., Eriksson A.G.Z., DucieJ.A., et al. Low-volume lymph node metastasis discovered during sentinel lymph node mapping for endometrial carcinoma. Ann Surg Oncol 2016;23(5):1653-1659. https://doi.org/10.1245/sl0434-0155040-z.St. Clair C.M., Eriksson A.G.Z., DucieJ.A., et al. Low-volume lymph node metastasis discovered during sentinel lymph node mapping for endometrial carcinoma. Ann Surg Oncol 2016;23(5):1653-1659. https://doi.org/10.1245/sl0434-0155040-z.

The authors declare that there are no conflicts of interest present.